CytoMed Therapeutics (FRA:F98) Debt-to-Equity : 0.04 (As of Dec. 2023)

View and export this data going back to 2023. Start your Free Trial

What is CytoMed Therapeutics Debt-to-Equity?

CytoMed Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.03 Mil. CytoMed Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €0.28 Mil. CytoMed Therapeutics's Total Stockholders Equity for the quarter that ended in Dec. 2023 was €7.74 Mil. CytoMed Therapeutics's debt to equity for the quarter that ended in Dec. 2023 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for CytoMed Therapeutics's Debt-to-Equity or its related term are showing as below:

FRA:F98' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.04 Med: 3.76 Max: 7.19
Current: 0.04

During the past 4 years, the highest Debt-to-Equity Ratio of CytoMed Therapeutics was 7.19. The lowest was 0.04. And the median was 3.76.

FRA:F98's Debt-to-Equity is ranked better than
76.71% of 1065 companies
in the Biotechnology industry
Industry Median: 0.14 vs FRA:F98: 0.04

CytoMed Therapeutics Debt-to-Equity Historical Data

The historical data trend for CytoMed Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytoMed Therapeutics Debt-to-Equity Chart

CytoMed Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

6.26

1.26

7.19

0.04

CytoMed Therapeutics Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial			1.26	2.16	7.19	0.04	0.04

Competitive Comparison of CytoMed Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, CytoMed Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CytoMed Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CytoMed Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where CytoMed Therapeutics's Debt-to-Equity falls into.

CytoMed Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

CytoMed Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.028	+	0.281)	/	7.741
	=	0.04

CytoMed Therapeutics's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.028	+	0.281)	/	7.741
	=	0.04

CytoMed Therapeutics (FRA:F98) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

CytoMed Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of CytoMed Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

CytoMed Therapeutics (FRA:F98) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytoMed Therapeutics Ltd (FRA:F98) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

GDTC:USA

Address

1 Commonwealth Lane, No. 08-22 One Commonwealth, Singapore, SGP, 149544

Website

https://w2.cytomed.sg

CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies into creating novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is majority revenue generator.

CytoMed Therapeutics (FRA:F98) Headlines

No Headlines